Clinical Trials
2 trialsNCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04471415 2023-06-12
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
Phase 1/2 Terminated